Event in Progress:
Discover the latest content that has just been published on Research Tree
Cantargia has presented new data from the Phase I/IIa CANFOUR trial at the American Association for Cancer Research (AACR) 2023 meeting. This included an interim analysis of patients (n=73) with pancreatic cancer (PDAC) receiving nadunolimab (an IL1RAP-targeting antibody) in combination with chemotherapy. Superior efficacy was observed in nadunolimab-treated patients relative to historical data of chemotherapy alone (median overall survival (mOS) of 12.9 months versus 8.5 months). Deeper and mor
Companies: CANTARGIA (CANTA:STO)Cantargia AB (CANTA:OME)
Edison
Cantargia is a clinical-stage biotechnology company with lead asset nadunolimab (CAN04) under assessment for several oncology indications. The company has announced that the first triple-negative breast cancer patient has been treated in the Phase II part of the TRIFOUR trial. The Phase Ib portion showed a favourable safety profile of the drug with early signs of efficacy. The Phase II portion is an open-label, randomised trial to compare nadunolimab in combination with chemotherapy agents gemci
Following a period of increased clinical activity, Q422, as we noted previously, saw Cantargia narrow its development focus to its three most promising/advanced programmes. In our opinion, this was driven by a combination of financing considerations (given the bearish biotech sentiment) and early efficacy signals. The clinical focus in FY23 will be on progressing it lead asset, nadunolimab (CAN04), in controlled, randomised trials in pancreatic cancer (PDAC), non-small cell lung cancer (NSCLC) a
Cantargia’s development programme for its lead asset, nadunolimab (CAN04), continued to build momentum in Q322. The company’s results for the period report an operating loss of SEK74.2m, which was largely driven by R&D expenses of SEK69.7m. Cash outflow from operations for Q322 was SEK81.4m, bringing the total cash used in operations for 9M22 to SEK297.3m, up from SEK256.6m in 9M21, due to expanded clinical activities. Cantargia received net proceeds from the rights issue completed in August 202
Cantargia has presented new data concerning its IL1RAP-targeting antibody, nadunolimab (CAN04), which demonstrates the drug’s ability to reduce levels of tumour-promoting molecules in a pancreatic cancer (PDAC) microenvironment model. Similar reductions have been observed in PDAC and non-small cell lung cancer (NSCLC) patients treated with nadunolimab. Importantly, an IL-1β targeting antibody showed no such effect (nadunolimab blocks both IL-1α and IL-1β activation). Investors will recall the fa
Cantargia has announced it has recruited enough patients into both of its Phase I CAPAFOUR and Phase I/II CESTAFOUR trials to end enrolment. Both studies are investigating the company’s lead asset nadunolimab (CAN04) in combination with chemotherapy for the treatment of pancreatic cancer (PDAC) in CAPAFOUR and in advanced solid tumours in CESTAFOUR. With recruitment complete, management will progress the clinical development of CAN04 through the planning of a randomised trial in non-small cell l
Cantargia announced the first patient treatment under the extension arm of its Phase Ib clinical trial CIRIFOUR, evaluating lead asset CAN04 (IL1RAP-binding antibody, nadunolimab) as first-line treatment for non-squamous non-small cell lung cancer (NSCLC) in combination with checkpoint inhibitor Keytruda (pembrolizumab) and platinum-based chemotherapy. The study will recruit up to 24 patients and is designed to incorporate a dose escalation phase and an optional evaluation phase using the optima
Research Tree provides access to ongoing research coverage, media content and regulatory news on CANTARGIA. We currently have 7 research reports from 1 professional analysts.
Share: